See the latest on 2022 State AG Elections
Menu

News & Insights

  • Clear

AG Moody Bans Eight Synthetic Opioids In Florida

On April 26, Florida AG Ashley Moody issued an emergency rule adding eight synthetic opioids to Florida’s Schedule I of controlled substances. The drugs, which are categorized as nitazenes, are available on the dark web and throughout the illegal drug market. They are not approved for medical use and , since 2020 alone, have been…

Read More

Kansas Recovers $27.6 Million from Pharmacy Benefit Manager for Alleged Overbilling of Medicaid

Kansas AG Derek Schmidt reached a settlement with pharmacy benefit manager Centene Corp. and its subsidiaries (collectively “Centene”) to resolve allegations that it overbilled the state’s Medicaid program. According to the AG’s office, Centene allegedly failed to represent Medicaid’s best interests in negotiations with pharmaceutical suppliers, failed to accurately report discounts it received on certain…

Read More

“Pharma Bro” Shkreli’s Former Pharmaceutical Company Pays $40 Million to Settle Antitrust Suit

A bipartisan group of AGs, led by New York AG Letitia James, and the FTC reached a settlement with pharmaceutical company Vyera Pharmaceuticals (formerly known as Turing Pharmaceuticals) and its parent company (collectively “Vyera”) as well as one of its former CEOs, Kevin Mulleady, to resolve allegations that Vyera engaged in anticompetitive and monopolistic practices in violation of the FTC Act, the Sherman Act, and state antitrust laws.

Read More

Potential for Future Competitive Harm Results in Divestiture Requirement for Generic Drug Company Acquisition

The Federal Trade Commission (“FTC”) reached a settlement with generic drug companies ANI Pharmaceuticals, Inc. (“ANI”) and Novitium Pharma LLC (“Novitium”), as well as Novitium’s parent company, to resolve allegations that ANI’s acquisition of Novitium would cause future harm to competition in markets for two generic medications in violation of the FTC Act and the…

Read More